drugset

drugset / Trial / NCT06434597

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

NCT06434597 ↗

Phase 2 Recruiting 60 enrolled Shanghai Pharmaceuticals Holding Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.

Timeline

Start: 2024-07-17
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPH5030	Small molecule	600 mg	Oral

Indications